Quantcast

Latest Monoclonal antibodies Stories

2014-04-03 20:22:32

SOUTH SAN FRANCISCO, Calif., April 3, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will be presenting at the following upcoming investor conference: -- 13(th) Annual Needham Healthcare Conference Tuesday, April 8, 2014 at the Westin Grand Central Hotel in New York City, NY 11:20AM - 11:50AM US ET (8:20AM - 8:50AM US PT) Presentations will include overviews of the company's KB001-A development program to...

2014-04-03 08:29:04

-- Phase 2 Clinical Trial Planned to Begin This Quarter -- SEATTLE, April 3, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that its Investigational New Drug Application (IND) to evaluate OMS721 for the inhibition of complement?mediated thrombotic microangiopathies (TMAs) has been cleared by the U.S. Food and Drug Administration (FDA). OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2),...

2014-04-03 04:20:52

CAMBRIDGE, England, April 3, 2014 /PRNewswire/ -- GBP19.5M raised to drive development of best-in-class fully human VH antibody fragment therapeutics Crescendo Biologics Limited (Crescendo) today announces it has raised a further GBP2m ($3.3m), from EMBL Ventures, in a final close of its Series A financing. Originally announced in December 2013, the Series A now totals GBP19.5m. It was led by Imperial Innovations and included new...

2014-04-01 00:21:53

SAN DIEGO, March 31, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced that the first patient has been dosed in the pivotal clinical trial designed to support approval of Cynviloq for the treatment of metastatic breast cancer and non-small cell lung cancer. The registration trial referred to as TRIBECA(TM) (TRIal designed to evaluate BioEquivalence...

2014-03-31 16:26:29

EMERYVILLE, Calif. and OSAKA, Japan, March 31, 2014 /PRNewswire/ -- Trianni, Inc. ("Trianni") and Takeda Pharmaceutical Company Limited ("Takeda") jointly announced today that they have entered into a license agreement for Takeda's use of the Trianni Mouse, a monoclonal antibody discovery platform. Distinguished by a novel chimeric gene segment design, the Trianni platform provides Takeda with easy access to a complete human antibody repertoire that has been optimized for the...

West Nile Virus May One Day Help Fight West Nile Virus
2014-03-30 05:57:16

Brett Smith for redOrbit.com - Your Universe Online Tobacco is commonly associated with causing disease, but a new methodology developed by scientists at Arizona State University and several other institutions uses the plant to generate a potential therapy for treating West Nile virus – which currently has no cure. According to a report published on Thursday in the open-access journal PLOS ONE, the team used tobacco to generate monoclonal antibodies (MAbs) and their derivatives, which...

2014-03-28 08:26:41

MONROVIA, Calif., March 28, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today presented an overview of its bispecific antibody programs at the Annual Summit on Practical and Emerging Trends in Multiple Myeloma being held in Whistler, British Columbia, Canada. The discussion featured Xencor's bispecific approach...

2014-03-27 12:31:03

LONDON, March 27, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Global and China Monoclonal Antibody Industry Report, 2013-2017 Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the market size of monoclonal antibody agents grew at a CAGR of 13%, far higher than the overall growth rate of...

2014-03-27 12:29:39

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/5sfksl/therapeutic_class ) has announced the addition of the "Therapeutic Class Overview: Psoriasis - Plaque Psoriasis & Psoriatic Arthritis - Novel Oral Drugs And Biologics To Change Future Treatment Paradigm" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and...

2014-03-27 08:34:12

Cannabinoid Receptor 1 is most recent GPCR to be targeted by RuiYi's iCAPS platform LA JOLLA, Calif. and SHANGHAI, March 27, 2014 /PRNewswire/ -- RuiYi, Inc. announced today a $15 million Series B financing by existing investors: 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA. RuiYi has a pipeline of...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.